COVID‐19 in a human T‐cell lymphotropic virus type‐1 carrier
Open Access
- 15 February 2022
- journal article
- case report
- Published by Wiley in Clinical Case Reports
- Vol. 10 (2) , e05463
Abstract
This is the first report of COVID‐19 in a human T‐cell lymphotropic virus type‐1 (HTLV‐1) carrier. HTLV‐1 infection can cause immune dysfunction even in asymptomatic carriers. This case highlights the need for guidance on management of COVID‐19‐HTLV‐1 coinfection, specifically on the appropriate use of corticosteroid treatment while considering secondary infection.Keywords
This publication has 13 references indexed in Scilit:
- Herpes simplex virus and cytomegalovirus reactivations among severe COVID-19 patientsCritical Care, 2020
- Co-infections in people with COVID-19: a systematic review and meta-analysisJournal of Infection, 2020
- Human T leukaemia Type 1 and COVID-19Pathogens, 2020
- Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, ChinaJournal of Infection, 2020
- Analysis of Epidemiological and Clinical Features in Older Patients With Coronavirus Disease 2019 (COVID-19) Outside WuhanClinical Infectious Diseases, 2020
- A retrospective analysis of false‐positive infectious screening results in blood donorsTransfusion, 2015
- Modulation of innate immune responses during human T-cell leukemia virus (HTLV-1) pathogenesisCytokine & Growth Factor Reviews, 2011
- Human T-lymphotropic virus 1: recent knowledge about an ancient infectionThe Lancet Infectious Diseases, 2007
- False positive antibody results against human T‐cell lymphotropic virus in patients with severe acute respiratory syndromeJournal of Medical Virology, 2005
- Impaired production of naive T lymphocytes in human T-cell leukemia virus type I–infected individuals: its implications in the immunodeficient stateBlood, 2001